Close X
Sunday, September 20th, 2020

Zenara Pharma receives DCGI approval to manufacture and sell Favipiravir tablets – Favizen

Tablets and API are 100% Made-in-India
Also exporting to global markets, including Middle East and Latin America


Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that it has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of Covid-19.The tablet, which will be sold under the brand name ‘Favizen’,is being manufactured at Zenara’s US FDA approved state-of-the-art facility in Hyderabad.


Dr. Jagadeesh Babu Rangisetty, Co-founder and Managing Director, says, “In the ongoing pandemic, it has become extremely critical for pharmaceutical companies to quickly provide safe and effective treatment options for patients with Covid-19. I am proud to say that we have our own in-house APIand are not dependent on any imports for the production. We believe that this will ensure stability and rapid production and availability of this treatment for the Indian market. We are also in talks with various institutions to make the tablets available at discounted or no cost to underprivileged patients.”


Zenara Pharma is in talks with multiple state institutions and several hospitals in India To ensure that Favizen is readily available for patients in need. The company is also likely to tie up with other partners across the country to increase patient coverage. Internationally, Zenarahas the manufacturing and distribution capabilities to improve access to this treatment around the world andhas already begun exports to the Middle East and Latin American countries.


So far, Favipiravir has demonstrated positive clinical outcomes in some trials and has already been approved for use to treat Covid-19 in Russia[i] and parts of the Middle East[ii]. Advanced stage trials are currently underway in several countries including India[iii]



Users Comment